`
`
`
`
`
`
`CONFIDENTIAL
`
` AGENCY TELEPHONE CONTACT REPORT
`
`
`PRODUCT: BG000012
`
`Application #: IND 73,061
`
`DATE/TIME OF CONTACT 26 April 2006
`OUTGOING:
`INCOMING:
`
`AGENCY REPRESENTATIVE(S):
`James Reese, Project Manager 301-796-1136
`Biogen Idec PARTICIPANT(S): Tammy Sarnelli
`
`
`
`SUBJECT:
`
`Submission of an End of Phase 2 Meeting Request While on Clinical Hold
`
`I called Jim Reese to inform him that Biogen Idec’s responses to the Clinical Hold have a target
`submission for late next week. He thanked me for informing him about the timing of this submission.
`
`I took the opportunity to ask Jim if he knew of any regulations that would prevent us from requesting
`an End of Phase 2 meeting while we are on clinical hold. Jim stated that we are entitled to request
`any meeting at any time, whether we are on clinical hold or not.
`
`He did caution that FDA could deny our request, but they would need to provide a clear explanation
`of the reason(s) for the denial (e.g. the meeting request did not meet the requirements put forth for
`Formal Meetings). He also stated that with FDA’s limited resources, we would not be able to have
`more than one EOP2 meeting. I clarified for Jim that it is our intention to have one EOP2 meeting
`whereby we would supply the data from a completed Phase 2 study (C-1900) and provide the Phase
`3 study designs for FDA feedback.
`
`Jim reminded me that we couldn’t begin a long-term study in the US until results from the 12-month
`non-human primate toxicology study have been submitted. I confirmed that this was our
`understanding from the Pre-IND meeting.
`
` thanked Jim for his time and the call was ended.
`
` I
`
`
`
`ACTION(S) REQUIRED
`FOLLOW-UP ACTIVITY
`RESPONSIBILITY
`Core Team to define timeline for EOP2 meeting
`T. Sarnelli et al.
`
`DATE DUE
`May 2006
`
`cc: Regulatory CMC, Regulatory Cambridge, Regulatory UK, BG12 Program Team
`
`
`
`Page 1 of 1
`
`
`
`
`Page 1 of 1
`
`Biogen Exhibit 2381
`Coalition v. Biogen
`IPR2015-01993
`
`